Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2651 participants.
Also called NCT01442038
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,651 participants
- Sponsor
- Registry
-
NCT01442038 -
2011-002507-15
-
- Main results
- Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial
- Other papers using this trial's data
- Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial
- Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01442038. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-07-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
- Acronym
- RIVER-PCI
- Condition
- Coronary Artery Disease
- Condition
- Angina Pectoris
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct01442038- Content hash
3fdd00734a2f8c78e3c1532aa77b184a7c6d58702a9c914c59717b6406cd437d